The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators

• Verfasst von: Kaistha, Brajesh Pratap [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Strobel, Oliver [VerfasserIn]
• Titel: The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators
• Verf.angabe: Brajesh P. Kaistha, Anja Krattenmacher, Johannes Fredebohm, Harald Schmidt, Diana Behrens, Miriam Widder, Thilo Hackert, Oliver Strobel, Jörg D. Hoheisel, Thomas M. Gress, Malte Buchholz
• Umfang: 11 S.
• Fussnoten: Gesehen am 14.07.2018
• Titel Quelle: Enthalten in: OncoTarget
• Jahr Quelle: 2017
• Band/Heft Quelle: 8(2017), 39, S. 66215-66225
• ISSN Quelle: 1949-2553
• DOI: doi:10.18632/oncotarget.19882
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 157760749X

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. With an overall five-year survival rate remaining below 6%, there is an explicit need to search for new molecular targets for therapeutic interventions. We undertook a barcode labelled short-hairpin (shRNA) library screen in pancreatic cancer cells in order to identify novel genes promoting cancer survival and progression. Among the candidate genes identified in this screen was the deubiquitinase USP5, which subsequent gene expression analyses demonstrated to be significantly upregulated in primary human pancreatic cancer tissues. Using different knockdown approaches, we show that expression of USP5 is essential for the proliferation and survival of pancreatic cancer cells, tested under different 2D and 3D cell culture conditions as well as in in vivo experiments. These growth inhibition effects upon knockdown of USP5 are mediated primarily by the attenuation of G1/S phase transition in the cells,which is accompanied by accumulation of DNA damage, upregulation of p27, and increased apoptosis rates. Since USP5 is overexpressed in cancer tissues, it can thus potentially serve as a new target for therapeutic interventions, especially given the fact that deubiquitinases are currently emerging as new class of attractive drug targets in cancer.